@article{article_532364, title={Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy}, journal={Osmangazi Tıp Dergisi}, volume={42}, pages={180–187}, year={2020}, DOI={10.20515/otd.532364}, author={Goren Sahin, Deniz and Dalva, Klara and Meriç, Sema and Gürman, Günhan and Özcan, Muhit and Arslan, Önder and Arat, Mutlu}, keywords={kronik miyelositer lösemi,akım sitometri,imatinib,T hücre}, abstract={<p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <span lang="en-us" style="font-size:10pt;font-family:’Times New Roman’, serif;" xml:lang="en-us">To analyze
T cell functions by flow cytometry and to evaluate the possible functional
changes that might occur under imatinib therapy in CML patients. A total of 29
patients and 9 healthy control subjects were enrolled. Newly diagnosed patients
having no treatment (group 1), patients receiving imatinib for 1 year (group 2)
and patients receiving imatinib more than 1 year (group 3), healthy control
subjects (group 4). IL-4 and IFN gamma expression on CD4+ cells; how much
percentage of CD3+ T cells were activated (CD3+CD69+); CD8+ T cells and the
ratio and grade of expression of HLA-ABC and HLA-DR on those cells were
evaluated, respectively. </span> </p> <p> </p> <p class="MsoNormal" style="margin:0cm 0cm .0001pt;font-size:medium;font-family:’Times New Roman’, serif;line-height:32px;"> </p> <p class="MsoNormal" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <span lang="en-us" style="font-size:10pt;font-family:’Times New Roman’, serif;" xml:lang="en-us">There was
no significant difference in terms of mean number of CD4+ cells between the
groups. However, there was a tendency towards higher CD4+ cells in control
group. IL-4 and IFN gamma were found not to be statistically significant
between the groups. Control group has lower IL-4 and IFN gamma expression
values. Mean number of CD4+ cells, which did not express IL-4 and IFN gamma,
were statistically higher in control group when compared to other groups. In
control group, % activation was decreased when compared to that of other
groups. CD8+ cell ratio was found to be statistically lower in all patient
groups (p=0.001). The expression of HLA-ABC and HLA-DR on CD8+ cells were
similar between the groups. We could not show any inhibitory effect of imatinib
on T cell functions in concordance with clinical experience and safety profile.  </span> </p> <p> </p> <p> </p>}, number={2}, publisher={Eskişehir Osmangazi Üniversitesi}